The pathogenesis and treatment of pulmonary infections in patients with cystic fibrosis

The Journal of Pediatrics

Volumn 98, Issue 2, 1981, Pages 173-179

  Marks, Melvin I ^a  

^a Department of Pediatrics ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AZLOCILLIN; BENOMYL; CARBENICILLIN; CEFALEXIN; CEFOPERAZONE; CEFOTAXIME; CLOXACILLIN; DICLOXACILLIN; ERYTHROMYCIN; GENTAMICIN; LATAMOXEF; METICILLIN; MEZLOCILLIN; PLACEBO; TICARCILLIN; TOBRAMYCIN;

ADOLESCENT; CYSTIC FIBROSIS; DRUG THERAPY; ENZYME LINKED IMMUNOSORBENT ASSAY; ETIOLOGY; MINIMUM INHIBITORY CONCENTRATION; PATHOGENESIS; PNEUMONIA; PRESCHOOL CHILD; PREVENTION; PSEUDOMONAS AERUGINOSA; RESPIRATORY SYSTEM; RESPIRATORY TRACT INFECTION; SCHOOL CHILD; STAPHYLOCOCCUS AUREUS; THERAPY;

ANIMAL; ANTIBIOTICS; CHILD; CYSTIC FIBROSIS; HUMAN; IMMUNOLOGIC TECHNIQUES; PNEUMONIA; PSEUDOMONAS INFECTIONS; RABBITS; RATS; RESPIRATORY TRACT INFECTIONS; SPUTUM; STAPHYLOCOCCAL INFECTIONS;

EID: 0019366004     PISSN: 00223476     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-3476(81)80631-2     Document Type: Article

References (60)

1. Cystic fibrosis
2. Pseudomonas aeruginosa infection in cystic fibrosis
3. The association of viral and mycoplasma infections with lower respiratory tract disease in patients with cystic fibrosis
4. Incidence of serum antibodies to several aspergillus species and to Candida albicans in cystic fibrosis
5. Research in cystic fibrosis
6. Research in cystic fibrosis
7. Research in cystic fibrosis
8. Extracellular toxins of Pseudomonas aeruginosa
9. Microscopic characterization of rabbit lung damage produced by Pseudomonas aeruginosa proteases
10. In vivo studies on protease and elastase from Pseudomonas aeruginosa
11. Antibodies to proteases and exotoxin A of Pseudomonas aeruginosa in patients with cystic fibrosis: demonstration by radioimmunoassay
12. Protective activity of antibodies to exotoxin A and lipopolysaccharide at the onset of Pseudomonas aeruginosa septicemia in man
13. Mucoid Pseudomonas aeruginosa
14. Production of mucoid microcolonies by Pseudomonas aeruginosa within infected lungs in cystic fibrosis
15. A rat model of chronic respiratory infection with Pseudomonas aeruginosa
16. The role of mucoid strains of Pseudomonas in the etiology of pulmonary infections in cystic fibrosis patients
17. Influence of mucoidy on antibody coating of Pseudomonas aeruginosa
18. Inhibitory effect of cystic fibrosis serum on Pseudomonas phagocytosis by rabbit and human alveolar macrophages
19. Development of cellular and humoral immunity in the respiratory tract of rabbits to Pseudomonas lipopolysaccharide
20. Immune complexes in cystic fibrosis
21. Immune complexes in cystic fibrosis
22. Lymphocyte responsiveness to Pseudomonas aeruginosa in cystic fibrosis. Relationship to status of pulmonary disease in sibling pairs
23. Staphylococcus aureus: Some host-parasite interactions
24. Bronchial infection in cystic fibrosis
25. Cell-mediated immune phenomena induced by lymphokines from splenic lymphocytes of mice with chronic staphylococcal infection
26. The key role of peptidoglycan in the opsonization of Staphylococcus aureus
27. Effect of protein A on staphylococcal opsonization
28. Quantitative culture and gram stain of sputum in pneumonia
29. A placebo-controlled trial of cephalexin therapy in the ambulatory management of patients with cystic fibrosis
30. Is antipseudomonas therapy warranted in acute respiratory exacerbations in children with cystic fibrosis? A controlled study comparing cloxacillin alone to a combination of carbenicillin-gentamicin
31. Pharmacokinetics of methicillin in patients with cystic fibrosis
32. Amikacin therapy of exacerbations of Pseudomonas aeruginosa infections in patients with cystic fibrosis
33. Double-blind controlled trial of tobramycin or placebo therapy for acute pulmonary exacerbations of cystic fibrosis
34. Bacterial colonization and clinical superinfection of the respiratory tract complicating antibiotic treatment of pneumonia
35. Safety of once daily therapy with high-dose tobramycin
36. Safety of long duration intravenous (IV) needles for administration of antibiotics to patients with cystic fibrosis (CF)
37. Outpatient intravenous medications in the management of cystic fibrosis
38. Effect of calcium and magnesium ions on the susceptibility of Pseudomonas species to tetracycline, gentamicin, polymyxin B, and carbenicillin
39. Mucoid Pseudomonas aeruginosa and cystic fibrosis: resistance of the mucoid form to carbenicillin, flucloxacillin and tobramycin and the isolation of mucoid variants in vitro
40. Multiple isolates of Pseudomonas aeruginosa with differing antimicrobial susceptibility patterns from patients with cystic fibrosis
41. Multiple antibiotic susceptibilities and serotypes of Pseudomonas aeruginosa isolates from single sputa of cystic fibrosis patients
42. Carbenicillin and gentamicin: Pharmacologic studies in patients with cystic fibrosis and Pseudomonas pulmonary infections
43. Carbenicillin: A clinical and laboratory evaluation
44. Summary of a workshop on infections in patients with cystic fibrosis
45. Azlocillin in respiratory tract infections with Pseudomonas aeruginosa in children with cystic fibrosis
46. Incidence and characteristics of antibiotic-tolerant strains of Staphylococcus aureus
47. Pseudomonas colonization in cystic fibrosis A study of 160 patients
48. Activity of newer aminoglycosides and carbenicillin, alone and in combination, against gentamicin-resistant Pseudomonas aeruginosa
49. Controlled comparison of amikacin and gentamicin
50. Nephrotoxicity with gentamicin or tobramycin
51. Hearing in patients with cystic fibrosis (CF) following longerm tobramycin administration
52. Delayed onset and reversible vestibulotoxicity of high dose tobramycin therapy to children with cystic fibrosis
53. HR 756, a highly active cephalosporin: Comparison with cefazolin and carbenicillin
54. LY-127935: A novel beta-lactam antibiotic with unusual antibacterial activity
55. In vitro antibacterial activity of cefoperazone (T-1551), a new semisynthetic cephalosporin
56. Comparative evaluation of piperacillin in vitro
57. Comparative study of antipseudomonas activity of azlocillin, mezlocillin, and ticarcillin
58. Treatment of pulmonary infections in patients with cystic fibrosis: A comparative study of ticarcillin and gentamicin
59. AT-2266, a new oral antipseudomonal agent
60. Pseudomonas aeruginosa infection in cystic fibrosis